The vaccine candidates are based on the VaxCelerate self-assembling vaccine platform. Credit: MasterTux from Pixabay.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Hoth Therapeutics has collaborated with Voltron Therapeutics to establish a joint venture (JV), HaloVax, for preclinical studies of vaccine candidates against Covid-19.

Vaccine candidates come from VaxCelerate self-assembling vaccine (SAV) platform, exclusively licensed by Voltron from the Massachusetts General Hospital (MGH)’s Vaccine and Immunotherapy Center (VIC).

Hoth Therapeutics and Voltron will work together to explore and develop SAV technology to fight the novel coronavirus infection.

VaxCelerate platform enables rapid development and pre-clinical testing of a new vaccine against specific pathogen targets.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

According to Hoth Therapeutics, the platform showed proof-of-concept in Lassa Fever.

The JV entity HaloVax will leverage the same SAV technology to create a potential Covid-19 vaccine.

VaxCelerate’s fixed immune adjuvant and variable immune targeting should provide benefits over other compounds in combination therapy.

Hoth Therapeutics added that the vaccine will act on DNA and internal / external mutated proteins to offer more targets for the immune system.

Vaccine and Immunotherapy Center translational medicine chief Dr Michael Callahan said: “We believe this SAV technology developed at the VIC, which has proof of concept data in infectious diseases and oncology in four animal models, has the potential to assist in the rapid development and testing of products to prevent, intercept or treat Covid-19.

“The customisable cellular immunity generated by the SAV may safely and effectively protect patients worldwide.”

As part of the deal, Hoth Therapeutics will be eligible for single-digit sales royalties on any products resulting from the alliance and will hold an option to acquire up to a 30% stake in HaloVax.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact